AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
Provided By GlobeNewswire
Last update: Sep 4, 2025
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here
Read more at globenewswire.comNYSEARCA:AIM (11/20/2025, 2:52:35 PM)
1.3
-0.03 (-2.26%)
Find more stocks in the Stock Screener
